AXIM Biotechnologies, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.001314 million compared to USD 0.008127 million a year ago. Net loss was USD 2.03 million compared to USD 3.29 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago. Basic loss per share was USD 0.01 compared to USD 0.03 a year ago. Diluted loss per share was USD 0.01 compared to USD 0.03 a year ago.
For the nine months, sales was USD 0.001314 million compared to USD 0.055651 million a year ago. Net loss was USD 5.34 million compared to USD 7.98 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.06 a year ago. Diluted loss per share from continuing operations was USD 0.04 compared to USD 0.06 a year ago. Basic loss per share was USD 0.034 compared to USD 0.06 a year ago. Diluted loss per share was USD 0.034 compared to USD 0.06 a year ago.